drugset
drugset / Trial / NCT06353152

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06353152 ↗

Phase 1 Unknown 12 enrolled Peking University Gracell Biopharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

A single-arm, open-label early-stage exploratory clinical study to evaluate the safety, tolerability and efficacy of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in subjects with gastric/gastroesophageal junction adenocarcinoma.

Timeline

Start
2023-11-17
Primary completion
2025-11-16
Completion
2025-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection Unknown — Other

Indications

gastric adenocarcinoma gastroesophageal junction adenocarcinoma